A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Ivan Titov, Richard G. Wunderink, Antoine Roquilly, Daniel Rodríguez Gonzalez, Aileen David-Wang, Helen W. Boucher, Keith S. Kaye, Maria C. Losada, Jiejun Du, Robert Tipping, Matthew L. Rizk, Munjal Patel, Michelle L. Brown, Katherine Young, Nicholas A. Kartsonis, Joan R. Butterton, Amanda Paschke, Luke F. Chen*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

120 Scopus citations

Fingerprint

Dive into the research topics of 'A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases